Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Dasatinib in KIT-Positive Patients With Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas

NCT00700882 is registered in ClinicalTrials.gov with Eastern Cooperative Oncology Group as lead sponsor.

NCT NCT00700882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00700882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Dasatinib in KIT-Positive Patients With Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas
Lead sponsor
Eastern Cooperative Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
July 2, 2009
Completion date
December 28, 2020
Enrollment
81 (actual)
Sites
153

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin)